New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Marcelo V. Negrao, Associate Professor of Thoracic and Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center and presenting author

“Responses lasting a median of more than a year in patients across all PD-L1 tumor expression levels - including many with low expression - is the type of progress we want to see in the first-line setting. The data presented at ESMO support continued study of olomorasib with immunotherapy, with or without chemotherapy, to give patients the possibility of more options from the outset of their treatment journey, where we successfully utilize other genomically-targeted therapies in lung cancer.”

Jacob Van Naarden, Executive Vice President and President of Lilly Oncology

“KRAS G12C-mutant lung cancer has been notoriously difficult to treat, and for most patients, the disease is so aggressive that the first line is their only line, underscoring just how critical that first treatment choice is. These results deepen our conviction in the role olomorasib could play in combination with standard PD1-based backbone therapy, while potentially offering a tolerability profile that doesn't require prophylactic medications. We recognize that the oncology community has been waiting for years for a targeted therapy regimen that can address first-line patients with G12C mutations, and we are hopeful that the pivotal Phase 3 data on olomorasib in combination with chemoimmunotherapy in the first half of next year will be a seminal moment for the field.”